Ask AI

Capsule Summaries

Share

Program Content

Activities

  • MK 8591A 052 Wk 96 DOR and ISL
    MK-8591A-052 Week 96: Switch From BIC/FTC/TAF to DOR/ISL in People Living With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 25, 2026

  • MK 8591A 051 Wk 96
    MK-8591A-051 Wk 96: Switch From Standard-of-Care ART to DOR/ISL in People Living With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 25, 2026

  • OPERA PrEP
    OPERA Cohort: PrEP Coverage and HIV Incidence With LA CAB vs Daily Oral FTC/TDF or FTC/TAF
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 26, 2026

  • ARTISTRY-1
    ARTISTRY-1: Phase III Trial of Single-Tablet BIC/LEN Switch vs Complex ART Continuation in People With HIV and Virologic Suppression
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 26, 2026

  • ARTISTRY-2
    ARTISTRY-2: Phase III Trial of Single-Tablet BIC/LEN Switch vs BIC/FTC/TAF Continuation in People With HIV and Virologic Suppression
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 26, 2026

  • LEN Case Series
    Case Series Evaluating Long-acting Lenacapavir in People With HIV and High Baseline Resistance
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 26, 2026

  • ANRS Prevenir
    ANRS Prévenir: Final Results of Prospective Observational Cohort Study of Daily or On-Demand Oral FTC/TDF HIV PrEP
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2026

  • MK-8527 PrEP
    MK-8527 PrEP: Phase I-II PK Analysis to Inform Dosing for EXPrESSIVE Phase III Trial Program
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2026

  • LA CAB + RPV in Adolescents
    IMPAACT 2017 Cohort 2: Wk 96 and End-of-Study Data After Switch to LA CAB + RPV in Adolescents Living With HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2026

  • Lenacapavir PrEP in Adolescent and Young Women
    PURPOSE 1: Long-term Follow-up of Twice-Yearly Lenacapavir PrEP in Adolescent and Young Women
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2026

  • Purpose 2 Longer Term Analysis
    PURPOSE 2 Longer-Term Analysis: Phase III Trial of HIV PreP With Twice-Yearly LEN vs Daily FTC/TDF in Cisgender Men and Gender Diverse People
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2026

  • LEN Resistance Mutations in PURPOSE
    PURPOSE 1 and PURPOSE 2: Randomized Blinded Phase Resistance Analysis With LEN PrEP
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2026

  • VOLITION
    VOLITION Primary Analysis: Phase III Trial of Early LA CAB + RPV Switch After Achieving Virologic Suppression With DTG/3TC in Treatment-Naive Adults With HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2026

  • EMBRACE
    EMBRACE: 12 Mo Results With Lotivibart + LA CAB for People Living With Virologically Suppressed HIV
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 27, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare